Symyx Joins MDL® Isentris Alliance
News May 04, 2006
Symyx Technologies, Inc. has joined the MDL® Isentris® Alliance. Collaborative efforts under the MDL Isentris Alliance are particularly important to research organizations and pharmaceutical companies that rely on multiple, specialized R&D software tools.
The ability to coordinate information flow between varieties of complex lab information systems is essential to effective, timely decision making.
"We're pleased that our partnership with Elsevier MDL will offer researchers more options for assembling informatics systems that utilize common, open technology platforms," said David Dorsett, General Manager of Symyx Software.
"The integration of the Symyx Software platform with the Isentris platform will be a welcome advantage to common customers and the research community."
Elsevier MDL Senior Vice President, Framework Development, Vikki Rehn, said, "The effective integration of research data and workflow applications offers R&D organizations a path to improved productivity."
"As major pharmaceutical research organizations move beyond industry-standard MDL ISIS technology to adopt the new-generation MDL Isentris platform, collaboration between leading informatics suppliers under the MDL Isentris Alliance enables rapid integration of specialty applications into a comprehensive research information system."
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019